|
Nitrilotriacetic Acid
|
DB03040 |
[A derivative of acetic acid, N(CH2COOH)3. It is a complexing (sequestering) agent that forms stable complexes with Zn2+. (From Miall's Dictionary of Chemistry, 5th ed.)] |
|
AL6528
|
DB04371 |
|
|
AZD-8186
|
DB15029 |
[AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery).] |
|
MK-1064
|
DB15028 |
[MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).] |
|
Girentuximab I-124
|
DB15025 |
[Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT).] |
|
Apararenone
|
DB15024 |
[Apararenone is under investigation in clinical trial NCT02531568 (Drug Interaction Study of Warfarin and MT-3995).] |
|
Adriforant
|
DB15027 |
[Adriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers).] |
|
CXA-10
|
DB15026 |
[CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).] |
|
Leriglitazone
|
DB15021 |
[Leriglitazone is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients).] |
|
Mureletecan
|
DB15020 |
[Mureletecan is under investigation in clinical trial NCT00004076 (PNU 166148 in Treating Patients With Metastatic Solid Tumors).] |
|
BMS-791826
|
DB15023 |
[BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).] |
|
Apomab
|
DB15022 |
[Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)).] |
|
S-Selanyl Cysteine
|
DB03049 |
|
|
3-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide
|
DB04378 |
|
|
L-Alpha-Phosphatidyl-Beta-Oleoyl-Gamma-Palmitoyl-Phosphatidylethanolamine
|
DB03047 |
|
|
6-Carboxymethyluracil
|
DB03048 |
|
|
N-Methyl-N-(Methylbenzyl)Formamide
|
DB04379 |
|
|
13-Acetylphorbol
|
DB04376 |
|
|
Pantothenyl-Aminoethanol-Acetate Pivalic Acid
|
DB03045 |
|
|
7-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-Carboximidamide
|
DB03046 |
|
